Covering the Cover Gastroenterology Anson W. Lowe, Richard H. Moseley  Gastroenterology  Volume 144, Issue 3, Pages 474-477 (March 2013) DOI: 10.1053/j.gastro.2013.01.030 Copyright © 2013 Terms and Conditions

Figure 1 Clinical phenotypes in the UK PBC patient cohorts. (A) Percentage of patients on UDCA therapy for a minimum of 2 years at the point of assessment at enrolment into the study who met Paris I criteria for response to UDCA, categorized according to their age at PBC diagnosis. Numbers of study subjects in each age group treated with UDCA for a minimum of 1 year are indicated. (B) Proportion of patients who did not meet the criteria for response to UDCA after a minimum of 2 years treatment based on the ALT/AST criterion (>2× the upper limit of normal) related to their age at presentation. (C) Severity of pruritus assessed using visual log scale, categorized according to the age at PBC diagnosis. (D) Severity of fatigue assessed using the PBC-40 fatigue domain at entry into the study. For both, numbers of study subjects in each age group in the cohort are indicated. Gastroenterology 2013 144, 474-477DOI: (10.1053/j.gastro.2013.01.030) Copyright © 2013 Terms and Conditions

Figure 2 MC4R expression influences the response to a roux-en-Y gastric bypass while on a high-fat diet. Gastroenterology 2013 144, 474-477DOI: (10.1053/j.gastro.2013.01.030) Copyright © 2013 Terms and Conditions

Figure 3 (A) Localization studies of microinjection sites, showing the immunofluorescence with anti-GFP antibody in the ARC (upper panel) and the immunohistochemistry of MCH-R in rats treated with a GFP- or MCH-R–expressing adenovirus in the ARC (lower panel). (B) Body weight change and cumulative food intake and (C) protein level profiles in liver of rats treated stereotaxically with aGFP-(red) or MCH-R-expressing adenovirus (blue) in the ARC. (B) Bodyweight change and cumulative food intake and (C) protein level profiles in liver after a 7-day infusion of saline (white) or MCH (6 μg/day) (black) specifically into the ARC. (D) Localization studies of microinjection, showing the immunofluorescence with anti-GFP antibody in theLHA (upper panel) and the immunohistochemistry ofMCH-R in rats treated with a GFP- or MCH-R–expressing adenovirus in the LHA (lower panel). (E) Body weight change and cumulative food intake and (F) protein level profiles in liver of rats treated stereotaxically with a GFP- (red) or MCH-R–expressing adenovirus (blue) in the LHA. (E) Body weight change and cumulative food intake and (F) protein level profiles in liver after a 7-day infusion of saline (white) or MCH (6_g/day) (black) specifically into the LHA. β-actin was used to normalize protein levels. Values are mean_standard error of the mean of 7–8 animals per group. *P < .05, **P < .01, and ***P < .001 vs controls. Gastroenterology 2013 144, 474-477DOI: (10.1053/j.gastro.2013.01.030) Copyright © 2013 Terms and Conditions